iVIEW Therapeutics
Overview
IVIEW Therapeutics is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Founded in 2015 by Bo Liang and John Baldwin, the company is based in Cranbury, New Jersey. As of the latest updates, it specializes in developing treatments for eye diseases like dry eye, myopia, and conjunctivitis, utilizing novel mechanisms and drug delivery technologies. IVIEW Therapeutics has raised approximately $55 million in funding across multiple rounds.
Recent Developments
- September 2024: IVIEW Therapeutics announced the completion of patient recruitment for its Phase 1/2 trial of IVW-1001, targeting the treatment of dry eye disease. The trial focuses on a novel TRPM8 agonist delivered via an ophthalmic eyelid wipe, with topline data expected in early 2025.
- March 2024: The U.S. FDA cleared IVIEW Therapeutics' IND application for their innovative IVW-1001 ophthalmic eyelid wipe, allowing the initiation of Phase 1/2 clinical trials aimed at evaluating its effects on dry eye disease.
- January 2024: The company announced a successful pre-IND meeting with the FDA, receiving full agreement on the development plans for IVW-1001, positioning it for clinical trials targeting dry eye disease.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2015 |
| Headquarters | Cranbury, New Jersey, USA |
| Founders | Bo Liang, John Baldwin |
| Revenue | Not yet generating sales revenue |
| Profits | Not applicable (Development stage) |
| Key Investors | BioAdvance, Proxima Ventures |
| Industry | Biotechnology, Ophthalmology |
| Number of Employees | Approximately 6 (as of December 2021) |
| Major Product Candidates | IVVIEW-1201, IVVIEW-1501, IVVIEW-1301 |
Early History
IVIEW Therapeutics was established in 2015 with a focus on developing novel ophthalmic therapeutics. Initial projects included IVIEW-1201 and IVIEW-1501, targeting conjunctivitis and sinusitis respectively. The company gained attention following a successful funding round led by BioAdvance and Proxima Ventures. Early development was marked by strategic formulation innovations and extensive preclinical trials aimed at addressing unmet medical needs in eye care. These efforts laid a foundation that set the stage for future clinical trials and IND applications.
Company Profile and Achievements
IVIEW Therapeutics operates with a strategic focus on advancing therapeutic solutions for ocular diseases through innovative drug delivery systems. Key achievements include:
- Successful IND Clearance: Achieved for IVW-1001, leading to significant advancement in dry eye treatment solutions.
- Funding Milestones: Raised over $55 million, reflecting investor confidence in its strategic direction.
- R&D Innovations: Development of the ophthalmic eyelid wipe, an innovative drug delivery method, which distinguishes its therapeutic approach.
- Pipeline Expansion: Exploration into gene therapy applications and development of treatments for broad ocular indications.
Current Operations and Market Position
IVIEW Therapeutics is actively conducting clinical trials and advancing its pipeline of innovative ophthalmic solutions. Its operations focus heavily on clinical-stage development with a robust portfolio that includes small molecules and potential gene therapies. The company differentiates itself with a unique drug delivery technology platform and a focus on novel mechanisms that address significant unmet needs in the ophthalmic sector.
Conclusion
IVIEW Therapeutics stands out in the biotechnology landscape for its dedicated approach to innovation in ophthalmic care. With ongoing clinical trials and a strategic emphasis on groundbreaking drug delivery methods, the company is poised to revolutionize treatment paradigms for ocular diseases. Continuous investor support and promising product pipelines indicate a strong potential for future contributions to eye care therapeutics, positioning IVIEW as a key player in its industry.